ArticleBMC cancer2016

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.

Simona Soverini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.